Helicobacter Infection
12
3
3
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 42/100
8.3%
1 terminated out of 12 trials
85.7%
-0.8% vs benchmark
42%
5 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (12)
The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection
An Observational Study for Gastric Cancer in Carriers of High Risk Helicobacter Pylori
Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection
Clinical Trial to Evaluate the Efficacy of Probit-Based Triple Therapy for Helicobacter Pylori Eradication
The Efficacy of the 7 Days Tailored Therapy as 2nd Rescue Therapy for Eradication of H. Pylori Infection
Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection
Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication
The Efficacy of the Tailored Therapy Based on Antimicrobial Susceptibility for 2nd Eradication of H. Pylori
Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection
Study of Pylopass Versus Placebo in Subjects Who Are Helicobacter Pylori Carriers and With Mild Indigestion
Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication
Standard Triple Therapy vs Sequential Therapy in Treatment of H Pylori Infection